## Aria CV, Inc. Completes First Closing of \$6.3 million Series A Financing

SAINT PAUL, MN—December 19, 2014—Aria CV, Inc., a developer of medical devices to treat heart failure related to pulmonary hypertension, today announced the initial closing of a \$6.3 million Series A preferred equity financing. The financing round was led by Catalyst Health Ventures and includes Broadview Ventures and Cedar Point Capital. The proceeds from this financing will be used to advance development and perform clinical testing of the device.

Aria CV is developing a medical device to treat patients with pulmonary hypertension or high blood pressure in the arteries of the lungs. In the classic form of the disease, pulmonary hypertension affects mostly women often in the prime of life. Pulmonary hypertension causes increased workload on the heart, leading to right heart failure. Employing a novel mechanism, Aria CV's device has the potential to improve outcomes by reducing the workload on the right heart.

"Even with optimal therapy, pulmonary hypertension is still considered a progressive disease with a poor prognosis," said John Scandurra DVM, Aria CV's President and CEO, "but our expert cardiologists believe Aria CV's device has the potential to improve both the quality and duration of life of patients suffering from the disease." Dr. Scandurra will be joined by Darshana Zaveri, Partner at Catalyst Health Ventures, and Dan Gladney, an experienced medtech executive, on the company's board of directors.

Dr. John Scandurra and Dr. Karl Vollmers, formerly Fellows at the University of Minnesota's Medical Devices Center, founded Aria CV and in connection with its founding, licensed certain patents from the University of Minnesota on an exclusive basis.

About Catalyst Health Ventures: Based in Boston, Massachusetts, Catalyst is a venture capital firm investing in disruptive solutions for global, unmet healthcare needs.

About Broadview Ventures: Broadview's mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

About Cedar Point Capital: Based in Minneapolis, MN, Cedar Point Capital is a boutique investment group that specializes in early stage medical technology companies based in the Twin Cities.

Contact Information John Scandurra, DVM Aria CV, Inc. jascandurra@ariacv.com